PEG-LYTE
Pre-Launchpolyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous
ANDAORALFOR SUSPENSION
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
PEG-LYTE (polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous) by Novartis is 3350 which causes water to be retained in the colon and produces a watery stool.
Drug data last refreshed 1w ago
Mechanism of Action
3350 which causes water to be retained in the colon and produces a watery stool
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Novartis
BASEL, Switzerland
Worked on PEG-LYTE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.